| VRTX:Vertex Pharmaceuticals Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.00% $0.00
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis |
|
| PR Newswire |
|
In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1and superior in reducing sweat chloride compared to TRIKAFTA- Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time - |
| Full Story → |
|
| Headline News |
|
| Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers |
| 8:30a ET July 9 '25 PR Newswire Europe |
|
|
| Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers |
| 8:30a ET July 9 '25 PR Newswire |
|
|
| Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers |
| 8:30a ET July 9 '25 CNW Group |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| September 3 '25. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, September 3 '25. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
1.17%
11.96% 
